Curis 10-Q Confirms $5.5M Offering, Going Concern Doubt Persists
CRIS sits 17% above its 52-week low of $1.54 on elevated volume (1.9× avg).
Summary
Curis's Q2 2026 10-Q confirms the $5.5 million August 2026 Public Offering and reiterates substantial doubt about its ability to continue as a going concern, with cash runway only into Q4 2026.
Key Events · Earnings and Guidance · CRIS
-
Going Concern Doubt Reiterated
The 10-Q states that conditions and events raise substantial doubt about Curis's ability to continue as a going concern within one year. With $5.1 million in cash as of June 30, 2026, plus $4.8 million net proceeds from the August 2026 offering, the company expects to fund operations only into the fourth quarter of 2026.
-
August 2026 Offering Completed
The August 2026 Public Offering was consummated on August 14, 2026, with gross proceeds of approximately $5.5 million and net proceeds of approximately $4.8 million. The offering included 335,001 shares of common stock at $1.50 per share with accompanying common warrants, and pre-funded warrants to purchase up to 3,398,333 shares at $1.49 per pre-funded warrant with accompanying common warrant.
-
Series B Warrant Termination Triggered
The January 2026 Series B Common Warrants will terminate 30 days after the Company announced dosing of the fifth patient in the Phase 2 CLL trial, which occurred on July 30, 2026. If the closing sale price is below $15.00, the exercise price will be reset to the closing sale price (not less than 50% of initial exercise price) and the termination date extended 30 days.
-
Nasdaq Compliance Regained
Curis regained Nasdaq compliance on July 24, 2026, following its reverse stock split, but is now subject to a Discretionary Panel Monitor for a one-year period.
Analysis · CRIS · Life Sciences
Curis's Q2 2026 10-Q confirms the completion of the August 2026 Public Offering with gross proceeds of $5.5 million and net proceeds of $4.8 million, but the company still has substantial doubt about its ability to continue as a going concern. The filing also reveals that the January 2026 Series B Common Warrants will terminate 30 days after the fifth patient was dosed in the Phase 2 CLL trial on July 30, 2026, with a potential exercise price reset if the stock price is below $15.00. With only $5.1 million in cash as of June 30, 2026, plus the $4.8 million net proceeds, the company expects to fund operations only into the fourth quarter of 2026, highlighting the urgent need for additional capital.
At the time of this filing, CRIS was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $1.54 to $39.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.